Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers

Leuk Res. 2005 Oct;29(10):1191-9. doi: 10.1016/j.leukres.2005.03.019.

Abstract

To better characterize acute myeloid leukemia (AML) development in non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice, we transplanted samples from patients with AML or KG-1 and EOL-1 cell lines. We found 9/12 primary AML samples and both cell lines to engraft within 2-8 weeks, with 5-80% human cells in bone marrow. Compared with freshly isolated AML cells, percentages of human CD33+, CD38+, CD31+ CD13+ or CD15+ subpopulations increased after transplantation, whereas percentages of CD34+ cells decreased. Engrafted mice frequently showed expression of human endothelial cell markers. Thus, transplantation of human AML into NOD/SCID mice reveals expression of hematopoietic and endothelial differentiation markers.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Animals
  • Antigens, Surface / metabolism*
  • Biomarkers, Tumor / metabolism*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / embryology
  • Endothelium, Vascular / pathology
  • Flow Cytometry
  • Humans
  • Leukemia, Myeloid / classification
  • Leukemia, Myeloid / immunology
  • Leukemia, Myeloid / pathology*
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Middle Aged
  • Phenotype
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transplantation, Heterologous / immunology
  • Transplantation, Heterologous / pathology*
  • Tumor Cells, Cultured

Substances

  • Antigens, Surface
  • Biomarkers, Tumor